Board of Directors

Dr. Ehud Geller has been active in the health care/biopharma and life science industries for over 30 years. The former president and CEO of Interpharm Laboratories, Ltd., he presided over the growth of this company from the seed stage to $18 million in revenues. Prior to that, Dr. Geller, was the president of the Pharmaceutical Division of Teva and Executive VP of the Teva Group, Israel´s largest pharmaceutical company. At Teva he led the merger of the pharmaceutical business involved in the acquisition of Ikapharm Ltd., and the strategy of Teva´s entry into the U.S. market. Earlier, Dr. Geller conducted pharmaceutical research at Wyeth Laboratories in the U.S. Dr. Geller has a B.Sc. degree in chemical engineering, an MBA from Columbia University, and a Ph.D. degree in pharma/chemical engineering from Drexel Institute. He serves as founder and director of biotech and device health care companies.

Mr. Dykan began his career with Andersen Consulting in New York and has over 25 years experience in finance, business development and general management in global growth companies and startups. He has had a lead role in managing investments of Vitalife, including arranging financings. Prior to joining Vitalife, he was Chairman and CEO of BitBand, an IP broadband start up, and held several senior financial positions, including as CFO at VocalTec Communications, as Director of Regional Finance for Applied Materials in Israel and VP Finance at Opal. Mr. Dykan is Chairman of Trig Medical and serves on board of directors of Deep Breeze, Quantomix, BetaO2, Genegrafts, Niti Surgical Solutions and the Technion Incubator. He has a B.S. in accounting and management from New York University and an MBA in computer applications also from New York University. Mr. Dykan is also licensed in New York State as a certified public accountant.

Dr. Eli Hazum received his Ph.D. degree from the Weizmann Institute of Science in 1978 in the area of hormone mechanisms. The author of more than 100 scientific publications in various areas of drug development, he started his professional career as a professor at the Weizmann Institute. Later, he spent 5 years at Glaxo Inc., in North Carolina as the department head of Receptor Research and Metabolic Diseases. Returning to Israel in 1992, Dr. Hazum served in various executive research positions at Biotechnology General Corp. and as V.P. of R&D at Peptor Ltd., before joining Medica Venture Partners as Chief Scientific Officer.

Click here for Mr. Tal's bio.